雌激素受体亚型在卵巢子宫内膜样癌组织中的表达

Study of Estrogen Receptor Subtypes Expression in Ovarian Endometrioid Carcinoma

目的 探讨雌激素受体亚型在卵巢子宫内膜样癌组织中的表达及其意义。方法 用 ER- α单克隆抗体和 ER- β多克隆抗体以免疫组化 SP法检测 30例卵巢子宫内膜样癌及 30例卵巢上皮性良性肿瘤石蜡切片ER- α和 ER- β的表达。结果 30例卵巢子宫内膜样癌组织中 ER- α阳性率 5 3.3% ,ER- β阳性率 4 6 .7% ;30例卵巢上皮性良性肿瘤中 ER- β阳性率 80 %明显高于 ER- α阳性率 30 % ,两种亚型表达之间无联系 (P>0 .0 5 )。 ER- α和ER- β的表达与 FIGO手术分期和组织学分级之间无联系 (P>0 .0 5 )。结论 以上提示 ER- α和 ER- β可能与卵巢子宫内膜样癌的发生有关 ,免疫组化

Objective This study was conducted to detect the expressions of the estrogen receptor subtypes in ovarian endometrioid carcinoma and elucidate the relationship and difference between their expressions and the carcinoma's clinicopathologic features. Methods Specific monoclonal antibody to human ER α and polyclonal antibody to human ER β were used and the immunohistochemical(IHC) assay was performed on 30 specimens of ovarian endometrioid carcinoma and benign ovarian epithelial tumors. Results ER α and ER β positive rates were 53.3% and 46.7% in the former specimens, 30% and 80% in the latter specimens respectively. There were no significant relationships between their expressions and the FIGO clinical phases or the histological stages. Conclusion The estrogen receptor subtypes may be involved in the genesis of ovarian endometrioid carcinoma. The IHC assay may be useful in choosing the treatment.